PitchBook-2024年四季度生物制药模式风险投资趋势（英）-2025_9页_10mb

Summary of Biopharma Modalities VC Trends Report (Q4 2024)

Overview

This report analyzes venture capital (VC) activities in the biopharma modalities ecosystem as of Q4 2024. It covers deal trends, investment focus, exit data, and market segments, based on PitchBook data through December 31, 2024.

Key Findings

• VC Activity in Q4 2024:
  • Deal count increased by 14.7% year-over-quarter to 234, with total funding decreasing 12.7% to $7.2 billion.
  • Trailing 12 months (TTM) funding grew by 20.3% year-over-year to $32.1 billion.
  • Investments favored later-stage clinical assets (e.g., phase 2+), particularly in cardiometabolic disorders and AI-driven drug discovery.
• Investment Trends:
  • Cardiometabolic disorders dominated, with GLP-1 drugs as a key theme; AI focus shifted to service models and infrastructure.
  • Deal value and count projections show moderate QoQ changes and TTMs.
• Exit Activity:
  • 23 exits occurred, including 12 IPOs and 11 M&A deals; exit value was $1,882.4 million.

Modalities Breakdown

• Mature modalities (e.g., antibodies, small molecules) led in deals and funding.
• Advancing modalities (e.g., gene editing, nucleic acid therapies) showed growth in early-stage investments.
• Emerging modalities (e.g., microbiome, oncolytic virus) had fewer deals but increasing interest from VC funds.

Segment Performance

• Deal count and value comparisons across mature, advancing, and emerging modalities indicate preferences for de-risked assets.
• Funding allocation: Mature modalities drove most activity, with TTM trends reflecting positive YoY growth.